MC
TEVA icon

Muhlenkamp & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Muhlenkamp & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-13,000
Closed -$246K – 61
2017
Q4 		$246K Hold
13,000
– – 0.07% 67
2017
Q3 		$229K Buy
+13,000
New +$293K 0.07% 68

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Muhlenkamp & Co's TEVA Position: Q1 2018 in Review

Muhlenkamp & Co sold out of Teva Pharmaceuticals (TEVA) in Q1 2018, closing a stake of 700 shares — an estimated $13K sold.

Muhlenkamp & Co first reported a position in TEVA in Q2 2013 and held it in 19 quarters. The position peaked at $11.6M in Q4 2015. 507 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

  • Muhlenkamp & Co reported no remaining Teva Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Muhlenkamp & Co sold 700 Teva Pharmaceuticals shares in Q1 2018, an estimated $13K.
  • Muhlenkamp & Co first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 19 quarters.
  • Muhlenkamp & Co's Teva Pharmaceuticals position peaked at $11.6M in Q4 2015.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on Muhlenkamp & Co's 13F filing for Q1 2018, filed 11 May 2018.